Practical articles organized by catalog use, documentation review, custom planning, and research procurement.
Choose a category to narrow the published guidance.
14 articles
The human evidence cited for TB-500 comes almost entirely from full-length thymosin beta-4 studies, not the TB-500 fragment itself. This article reviews what each study actually used.
Read guidance →
The Paradigm Peptides case is not just commercial fraud — it left real health harm behind. This article reviews the customer reports listed by the Department of Justice, and the full progression of Daniel Murphy from insomnia to steroid-induced psychosis.
Read guidance →
CJC-1295 trial records show headache, diarrhea, injection-site reactions, and increased heart rate; Ipamorelin’s record is gentler but thinner. This article reviews trial data and community reports.
Read guidance →
GLOW, KLOW, and the Wolverine stack are all peptide blends, but their components, ratios, and adjustability differ. This article uses a comparison table to clarify the real differences.
Read guidance →
Cagrilintide titrated to 2.4 mg weekly in trials; the 4.5 mg dose was dropped for higher nausea rates. Community protocols copy semaglutide's titration schedule and come from no cagrilintide trial. This article compares the two, and explains why a 5:1 premixed vial cannot be dosed independently.
Read guidance →
Retatrutide’s side effects are well documented in trials: gastrointestinal reactions, increased heart rate, skin sensitivity, and rare pancreatic and gallbladder events. This article reviews the data by system.
Read guidance →
Ipamorelin and tesamorelin both act on the growth hormone system, but their evidence strength and approval status differ sharply. This article compares their mechanisms, clinical data, and practical boundaries.
Read guidance →
Oral or injectable? This is one of the most debated topics around BPC-157. This article explains gastric stability, systemic bioavailability, half-life data, and why it currently cannot be proven that oral and injectable forms are equally effective.
Read guidance →
Peptide drugs are becoming a major direction in the treatment of metabolic diseases and cancer. This article explains why pharmaceutical companies are investing heavily in peptides, how conjugates enable targeted delivery, how half-life issues are addressed through PEGylation and lipidation, and how cell-penetrating peptides deliver drugs into cells.
Read guidance →
Two Phase 2 Trials Published Simultaneously in NEJM: Tirzepatide and Survodutide Both Significantly Outperform Placebo in Patients with MASH and Liver Fibrosis, Supporting Larger Phase 3 Trials. Tirzepatide Achieved MASH Resolution Rates of Up to 62% at 52 Weeks, and Survodutide Up to 62% at 48 Weeks.
Read guidance →
A practical checklist for identifying a catalog record and giving the review team enough information to answer accurately.
Read guidance →
Understand the difference between a catalog statement, a mapped historical file, and documentation for the material currently being quoted.
Read guidance →
The sequence, modification, purity, quantity, analytical, destination, and timing details that make a custom request reviewable.
Read guidance →
A controlled way to compare identity, specification, evidence, destination requirements, and lead time before a purchase decision.
Read guidance →